Cic edizioni internazionali
Clinical Cases in mineral and bone metabolism

Current medical treatment strategies concerning fracture healing

Mini-reviews, 116 - 120
doi: 10.11138/ccmbm/2013.10.2.116
Tag this article
Abstract
Enhanced HTML Full text PDF
The morbidity and socioeconomic costs associated with bone healing are considerable. A number of fractures are complicated by impaired healing. This is prevalent in certain risk groups such as elderly, osteoporotics, postmenopausal women, and in people with malnutrition.
The biologic process of fracture healing is complex and impacted by multiple factors. Some of them, such as the nutritional and health conditions, are patient-dependent, while others depend on the trauma experienced and stability of the fracture. Fracture healing disorders negatively affect the patient’s quality of life and result in high healthcare costs, as a second surgery is required to stabilize the fracture and stimulate bone biology. Future biotechnologies that accelerate fracture healing may be useful tools, which might also prevent the onset of these disorders.
We list the characteristics of the drugs used for osteoporosis, but we point out in particular the use of strontium ranelate and teriparatide in our clinical practice in elderly patients, especially females, who reported fractures with risk of nonunion.
This medical treatment could impaired fracture healing however, most of the evidence is obtained in animal studies and very few studies have been done in humans.
Thus one could hypothesize the possibility of a medical treatment both as a preventive and as support to the synthesis.
However, no clinical studies are available so far, and such studies are warranted before any conclusions can be drawn.
A positive effect of osteoporosis treatments on bone healing is an interesting possibility and merits further clinical research.

Vol. XIV (No. 1) 2017 January - April

  1. From the Editor-in-Chief
    Brandi M.L.
    doi: 10.11138/ccmbm/2017.14.1.011
  2. Low-dose diclofenac in patients with fragility fractures
    Vannucci L., Fossi C., Gronchi G., Brandi M.L.
    doi: 10.11138/ccmbm/2017.14.1.015
  3. Vitamin D levels and their impact on mineral metabolism in HIV infected patients: an exploratory study
    Mastaglia S., Watson D., Bello N., Fridman V., Stecher D., Oliveri B.
    doi: 10.11138/ccmbm/2017.14.1.018
  4. New quantitative ultrasound techniques for bone analysis at the distal radius in hip fracture cases: differences between femoral neck and trochanteric fractures
    Horii M., Fujiwara H., Sakai R., Sawada K., Mikami Y, Toyama S., Ozaki E., Kuriyama N., Kurokawa M., Kubo T.
    doi: 10.11138/ccmbm/2017.14.1.023
  5. Use of teriparatide off-label: our experience and review of literature
    Ciurlia E., Tranquilli Leali P., Doria C.
    doi: 10.11138/ccmbm/2017.14.1.028
  6. The effects of zoledronic acid on ECG: a prospective study on patients with bone metastatic cancer
    Demirtas D., Bilir C., Demirtas A.O., Engin H.
    doi: 10.11138/ccmbm/2017.14.1.035
  7. A comparison of two fixation methods for femoral trochanteric fractures: a new generation intramedullary system vs sliding hip screw
    Carulli C., Piacentini F., Paoli T., Civinini R., Innocenti M.
    doi: 10.11138/ccmbm/2017.14.1.041
  8. The use of cholecalciferol in patients with hip fracture
    Cianferotti L., Parri S., Gronchi G., Civinini R., Brandi M.L.
    doi: 10.11138/ccmbm/2017.14.1.048
  9. Evaluation of bone microstructure in CRPS-affected upper limbs by HR-pQCT
    Mussawy H., Schmidt T., Rolvien T., Rüther W., Amling M.
    doi: 10.11138/ccmbm/2017.14.1.054
  10. Molecular genetics in primary hyperparathyroidism: the role of genetic tests in differential diagnosis, disease prevention strategy, and therapeutic planning. A 2017 update
    Marini F., Cianferotti L., Giusti F., Brandi M.L.
    doi: 10.11138/ccmbm/2017.14.1.060
  11. Bone health in menopausal women: a role for General Practitioners
    Michieli R., Musto M.
    doi: 10.11138/ccmbm/2017.14.1.071
  12. Legg-Calvé-Perthes disease: classifications and prognostic factors
    Rampal V., Clément J.-L., Solla F.
    doi: 10.11138/ccmbm/2017.14.1.074
  13. Transient osteoporosis of the hip with a contralateral delayed involvement: a case report
    Iannò B., De Gori M., Familiari F., Pugliese T., Gasparini G.
    doi: 10.11138/ccmbm/2017.14.1.083
  14. A case report: hypercalcemia due to vitamin supplementation in a patient with neurofibromatosis
    Crone M., Fogarty K.
    doi: 10.11138/ccmbm/2017.14.1.087
  15. Is this a seizure?
    Franceschet G., Mazzucato M., Censi S., Simmini S., Boscaro M., Camozzi V.
    doi: 10.11138/ccmbm/2017.14.1.089
  16. Histological and micro Computed Tomography analysis of a femoral stress fracture associated with prolonged bisphosphonate use
    Somford M.P., van Ruijven L.J., Kloen P., Bakker A.D.
    doi: 10.11138/ccmbm/2017.14.1.092
  17. Primary hyperparathyroidism associated to thrombocytopenia: an issue to consider?
    De Keukeleire S., Muylle K., Tsoumalis G., Vermeulen S., Vogelaers D.
    doi: 10.11138/ccmbm/2017.14.1.097
  18. Acute severe diarrhoea and hyponatremia after zoledronic acid infusion: an acute phase reaction
    Shafi Kuchay M., Farooqui K.J., Mithal A.
    doi: 10.11138/ccmbm/2017.14.1.101
  19. LoCa LoPa myelopathy: is prevention better than cure?
    Pandita K.K., Razdan S., Pandita S.
    doi: 10.11138/ccmbm/2017.14.1.105
Last Viewed articles: la lista degli ultimi x visitati.
  1. Current medical treatment strategies concerning fracture healing
    Giannotti S., Bottai V., Dell'osso G., Pini E., De Paola G., Bugelli G., Guido G.
    doi: 10.11138/ccmbm/2013.10.2.116
credits